LCM
SLDB icon

Laurion Capital Management’s Solid Biosciences SLDB Stock Holding History

Laurion Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-255,077
Closed -$1.02M – 376
2024
Q4 		$1.02M Hold
255,077
– – 0.02% 205
2024
Q3 		$1.78M Sell
255,077
-234,601
-48% -$1.9M 0.02% 166
2024
Q2 		$2.78M Sell
489,678
-438,491
-47% -$3.93M 0.03% 193
2024
Q1 		$12.4M Hold
928,169
– – 0.1% 167
2023
Q4 		$5.7M Hold
928,169
– – 0.05% 235
2023
Q3 		$2.34M Hold
928,169
– – 0.01% 325
2023
Q2 		$4.86M Hold
928,169
– – 0.03% 263
2023
Q1 		$4.4M Hold
928,169
– – 0.03% 243
2022
Q4 		$4.99M Buy
928,169
+851,062
+1,104% +$5.58M 0.02% 268
2022
Q3 		$540K Hold
77,107
– – ﹤0.01% 395
2022
Q2 		$712K Buy
+77,107
New +$801K 0.01% 312
2018
Q2 		– Sell
-14,413
Closed -$1.62M – 1559
2018
Q1 		$1.62M Buy
+14,413
New +$4.87M 0.01% 697

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's SLDB Position: Q1 2025 in Review

Laurion Capital Management sold out of Solid Biosciences (SLDB) in Q1 2025, closing a stake of 255,077 shares — an estimated $1.02M sold.

Laurion Capital Management first reported a position in SLDB in Q1 2018 and held it in 12 quarters. The position peaked at $12.4M in Q1 2024. 124 funds tracked by Wall St. Rank hold SLDB as of Q1 2025.

  • Laurion Capital Management reported no remaining Solid Biosciences position as of Q1 2025 after selling out during the quarter.
  • Laurion Capital Management sold 255,077 Solid Biosciences shares in Q1 2025, an estimated $1.02M.
  • Laurion Capital Management first reported a position in Solid Biosciences in Q1 2018 and held it in 12 quarters.
  • Laurion Capital Management's Solid Biosciences position peaked at $12.4M in Q1 2024.
  • 124 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2025.

Based on Laurion Capital Management's 13F filing for Q1 2025, filed 15 May 2025.